H eart failure is the leading cause of cardiovascular morbidity and mortality worldwide. 1 Up to 50% of heart failure patients have diastolic dysfunction. 2 One of the main causes of diastolic dysfunction is cardiac fibrosis characterized by a pathological accumulation of fibrillar collagen throughout the myocardium, which results in reduced cardiac muscle compliance, impaired filling, and ultimately heart failure. 3, 4 
Clinical Perspective on p 593
In the heart, collagen is produced primarily by cardiac fibroblasts. In response to stress, profibrotic cytokines are released, leading to cardiac fibroblast proliferation and trans-formation into myofibroblasts. Myofibroblasts have contractile fibers containing ␣-smooth muscle actin (␣-SMA) and are responsible for the excessive accumulation of extracellular matrix under pathological conditions. 3, 5 Therefore, abrogation of cardiac fibroblast transformation into myofibroblasts is 1 strategy for suppressing cardiac fibrotic remodeling, which can lead to heart failure.
Cardiac fibroblast transformation is induced primarily by transforming growth factor (TGF)-␤1, 6, 7 which, under pathological conditions, can result in excessive collagen production. 8 TGF-␤1 binds to type II (TGF␤RII) and type I (TGF␤RI) receptors, which phosphorylate TGF␤RI-associated Smad2 and Smad3. Phosphorylated Smad2/3 binds Smad4 and translocates into the nucleus, where it promotes gene transcription. 8 Therefore, inhibition of phosphorylation and/or nuclear translocation of Smad2/3 are potential targets for suppressing the fibrotic effects of TGF-␤1. 9 The cyclic GMP (cGMP)/protein kinase G (PKG) signaling pathway inhibits TGF-␤1-induced cardiac fibrosis by blocking TGF-␤1-induced nuclear translocation of phospho-Smad3 through PKG-induced phosphorylation of Ser309 and Thr388 sites in the MH2 domain of the Smad3 protein. 9, 10 Omega-3 polyunsaturated fatty acids (-3 PUFAs; particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) protect against coronary artery disease and heart failure. [11] [12] [13] The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico Italian (GISSI) heart failure trial indicated that -3 PUFAs (EPAϩDHA, 0.85 g/d) significantly reduced mortality in patients with chronic heart failure. 14 However, there is little information on the impact of -3 PUFAs on the progression of cardiac fibrosis and diastolic heart failure. Interestingly, EPA and DHA increase cGMP levels in neonatal rat cardiac myocytes. 15 This suggests that -3 PUFAs may have an antifibrotic effect in the heart through the cGMP/PKG pathway.
The present study demonstrates that -3 PUFAs inhibit the cardiac fibrotic response and prevent progression of cardiac dysfunction by suppression of cardiac fibroblast proliferation, transformation, and collagen production. These antifibrotic effects of -3 PUFAs are exerted through the activation of the cGMP/PKG pathway, which blocks the TGF-␤1-stimulated nuclear translocation of phosphorylated Smads.
Methods
Detailed methods are available in the online-only Data Supplement.
Animals
Male C57BL/6 mice (5 weeks of age; Jackson Laboratory, Bar Harbor, ME) were fed a control or a fish oil-supplemented diet for 8 weeks (Dyets, Bethlehem, PA). Both diets contained 4% by weight test oil (control diet, 40 g corn oil per 1 kg; fish oil-supplemented diet, 12 g menhaden oil plus 28 g corn oil per 1 kg) but were otherwise identical. The fish oil diet provided 1% energy as EPAϩDHA. After 8 weeks on the assigned diet, mice were randomly allocated into 4 groups using a 2ϫ2 factorial design and subjected to transverse aortic constriction (TAC) surgery (groups: control/sham, control/TAC, fish oil/sham, fish oil/TAC; nϭ22 to 25 per group). After surgery, mice were continually fed the assigned diets and euthanized after 3, 7, or 28 days.
Transverse Aortic Constriction
TAC surgery was performed without intubation under anesthesia with isoflurane, as previously described. 16, 17 
Measurement of Cardiac Function
Echocardiography and hemodynamics were performed as described previously. 18
Measurement of the -3 Content
The -3 content in red blood cells and cardiac tissues was measured as previously described. 19 A similar analysis was performed on cultured cardiac fibroblasts.
Isolation and Culture of Adult Mouse Cardiac Fibroblasts

Western Blot, Immunohistochemistry, and Immunocytochemistry
Western blot, immunohistochemistry, and immunocytochemistry were performed as standard procedures as detailed in the Methods section of online-only Data Supplement.
Figure 1.
Fish oil prevents pressure overload-induced cardiac dysfunction. A, The -3 content (EPAϩDHA, percent of total fatty acids) of red blood cells or left ventricle (LV) determined by gas chromatography 4 weeks after TAC. B, Fractional shortening (FS) determined by echocardiography before and 1, 2, and 4 weeks after TAC. For analysis of FS, a repeated measures model was used. FS in control diet/sham animals was not changed (0.7Ϯ0.8%; PϾ0.2) compared with baseline, nor was FS in fish oil/sham animals (1.5Ϯ1.1%; Pϭ0.2). TAC had the effect of decreasing FS by Ϫ4.4Ϯ1.0%/wk (Pϭ0.0003), and fish oil reversed the TAC effect by 3.1Ϯ1.5%/wk (Pϭ0.043), almost three quarters of the effect of TAC surgery. C and D, Contractility (ϮdP/dt) and end-diastolic pressure determined from hemodynamic measurements 4 weeks after TAC. Data are presented as meanϮSEM with nϭ6 in the control/sham and fish oil/sham groups and nϭ8 to 9 in the control/TAC and fish oil/ TAC groups. In A, C, and D, data were analyzed by 2-way ANOVA with the Tukey posthoc test.
Measurement of TGF-␤1, cGMP, and Nitrite/Nitrate Concentrations
The active form of TGF-␤1 levels was measured by an ELISA kit (R&D Systems, Minneapolis, MN). cGMP levels were quantified with the acetylation protocol for a competitive cGMP enzyme immunoassay (Cayman Chemical, Ann Arbor, MI). Nitrite/nitrate concentrations were determined with the Total Nitrate/Nitrite Fluorometric Assay kit (Cayman Chemical).
Statistics
Results are reported as meanϮSEM. Means were compared by 1-way or 2-way ANOVA followed by the Tukey posthoc test or Dunnett posthoc test as appropriate. Values of PϽ0.05 were considered significant. For analysis of fractional shortening ( Figure 1B ), longitudinal analysis with restricted maximum likelihood estimation method and an unstructured correlation matrix for the repeated measurements was used (SAS version 9.2; SAS Institute Inc, Cary, NC).
Results
Fish Oil Prevents Pressure Overload-Induced Cardiac Dysfunction
Before pressure overload was induced, mice were fed a diet supplemented with -3 PUFAs for 8 weeks. This increased the -3 content (EPAϩDHA, % of total fatty acids) in both red blood cells (3.4-fold) and the left ventricle (2.4-fold) relative to mice on the control diet ( Figure 1A and Tables I and II in the online-only Data Supplement). Aortic constriction decreased the -3 content in red blood cells and heart in mice fed the control diet (PϽ0.01), whereas it had no effect on the fish oil groups ( Figure 1A and Tables I and II in the online-only Data Supplement). As expected, in mice fed the control diet, aortic constriction induced contractile dysfunction by 4 weeks after surgery, as evidenced by a 38% decrease in fractional shortening, decreases of 29% in dP/ dtmax and 27% in dP/dtmin, and a 6.5-fold increase in end-diastolic pressure (all at least PϽ0.05 relative to sham). Conversely, contractile dysfunction was prevented after aortic constriction in mice fed the fish oil diet ( Figure 1B through 1D ). There was no significant difference in pressure gradients induced by aortic constriction between the control diet and fish oil diet groups (Table III in the online-only Data Supplement). In short, dietary supplementation with fish oil protects against pressure overload-induced contractile dysfunction.
Fish Oil Prevents Pressure Overload-Induced Cardiac Fibrosis in the Left Ventricle
To determine whether dietary supplementation with fish oil prevents pressure overload-induced cardiac fibrosis, tissues were stained with Picrosirius Red to detect collagen distribution in left ventricular cross sections 4 weeks after surgery. In mice fed the control diet, aortic constriction induced significant fibrosis. The collagen content was increased 4.6-fold over sham (Figure 2A and 2B ). This was accompanied by a significant increase in collagen I and III expression at both 3 and 7 days after surgery (collagen I: 5.3-fold at 3 days, 4.2-fold at 7 days; collagen III: 7.2-fold at 3 days, 8.0-fold at 7 days; Figure 2C and 2D). However, in mice fed the fish oil diet, fibrosis was increased only 2.0-fold over sham, and there was no induction of collagen expression, resulting in 63% less fibrosis compared with the mice fed the control diet. In summary, fish oil consumption prevents fibrosis induced by pressure overload.
A previous report indicated that dietary supplementation with fish oil reduced hypertrophy after aortic constriction in rats. 20 Here, aortic constriction induced a hypertrophic response as evidenced by a 42% increase in the ratio of heart weight to body weight in mice fed the control diet and a 31% increase in the ratio of heart weight to body weight in mice fed the fish oil diet. However, after adjustment for the effect of fish oil, aortic constriction increased the ratio of heart weight to body weight by 1.9Ϯ0.3 in both the control and fish oil groups ( Figure 2E ). Conversely, in mice fed the control diet, aortic constriction significantly induced the expression of the hypertrophic marker genes atrial (ANP) and brain natriuretic peptide (BNP), which was not observed in mice fed the fish oil diet ( Figure 2F and 2G).
Fish Oil Blocks Pressure Overload-Induced Nonmyocyte Proliferation and Myofibroblast Transformation
To determine how fish oil feeding affected cardiac fibroblast proliferation and transformation after aortic constriction, we stained ventricular sections for interstitial expression of Ki67 (excluding myocytes, which were counterstained with phalloidin) as a marker of nonmyocyte proliferation and for expression of ␣-SMA as a marker of fibroblast transformation (excluding the vascular staining) ( Figure 3A and 3B). In mice fed the control diet, aortic constriction induced a significant increase in the number of interstitial Ki67-positive cells and ␣-SMA-positive area, whereas dietary supplementation with fish oil prevented nonmyocyte proliferation and fibroblast transformation ( Figure 3C and 3D). These findings indicate that fish oil prevents fibroblast proliferation and transformation, which can explain why fish oil prevented fibrosis and contractile dysfunction in this model.
Fish Oil Does Not Block Pressure Overload-Induced TGF-␤1 Production or Phosphorylation of Smad2
To determine whether dietary supplementation with fish oil interfered with TGF-␤1 signaling after aortic constriction, we measured the active form of TGF-␤1 levels 3 days after surgery and Smad2 phosphorylation levels 3 days and 4 weeks after surgery. Interestingly, aortic constriction increased TGF-␤1 levels and Smad2 phosphorylation to a similar degree in both groups ( Figure 4A through 4C). Therefore, dietary supplementation with fish oil does not interrupt TGF-␤1 production and Smad2 phosphorylation induced by aortic constriction. We also tested Smad3 phosphorylation levels at 3 days and 4 weeks after TAC, but Smad3 phosphorylation was not detected at either time point in the heart tissues (data not shown).
EPA and DHA Inhibit the TGF-␤1-Stimulated Fibrotic Response in Isolated Adult Mouse Cardiac Fibroblasts
To explain the antifibrotic effects of dietary fish oil we observed in vivo, we investigated EPA-and DHA-(the 2 primary -3 PUFAs in fish oil) mediated inhibition of profibrotic TGF-␤1 signaling in isolated adult mouse cardiac fibroblasts. EPA (10 mol/L) and DHA (10 mol/L) significantly increased the -3 content by 2.3-fold and 1.65-fold, respectively. Neither arachidonic acid (-6 PUFA) nor oleic acid (-9 PUFA) altered the -3 content ( Figure 5A ). TGF-␤1 (1 ng/mL) significantly increased proliferation by 142% (PϽ0.01; Figure 5B ), collagen synthesis by 190% (PϽ0.01; Figure 5C ), and myofibroblast transformation by 66% (PϽ0.01; Figure 5D and 5E), whereas EPA and DHA at 10 mol/L had no effect on these parameters. However, both EPA and DHA (10 mol/L) completely blocked TGF-␤1induced cardiac fibroblast proliferation, prevented collagen synthesis, and significantly decreased myofibroblast transformation (all PϽ0.01 versus TGF-␤1-treated cardiac fibroblasts; Figure 5B through 5E). The other fatty acids, arachidonic acid (10 mol/L) and oleic acid (10 mol/L), did not affect TGF-␤1-induced collagen synthesis in cardiac fibroblasts ( Figure 5B and 5C ). These results demonstrate that the antifibrotic effects of -3 PUFAs are mediated by suppression of TGF-␤1-induced fibrosis in cardiac fibroblasts.
EPA and DHA Inhibit the TGF-␤1-Stimulated Fibrotic Response Through the cGMP/PKG Pathway
The cGMP/PKG signaling pathway plays a counterregulatory role against TGF-␤1-induced cardiac fibrosis. 9, 10 We therefore tested the hypothesis that -3 PUFAs activate cGMP/ PKG signaling and block profibrotic TGF-␤1 signaling. In cultured cardiac fibroblasts, both EPA and DHA (10 to 50 mol/L) induced dose-dependent increases in cGMP production (all PϽ0.01), but neither control fatty acid, arachidonic acid or oleic acid (10 or 20 mol/L), was able to induce cGMP production ( Figure 6A ). Furthermore, EPA (10 mol/L), DHA (10 mol/L), and 8-bromo-cGMP (1 mmol/L), which activates PKG, completely blocked the TGF-␤1-induced collagen synthesis ( Figure 6B ). Conversely, a peptide-based inhibitor of PKG, DT-3 (1 mol/L), significantly diminished the antifibrotic effect of EPA, DHA, and cGMP ( Figure 6B ). In summary, these results indicate that the inhibition of profibrotic TGF-␤1 signaling by -3 PUFAs is mediated by -3 PUFA-induced cGMP/PKG signaling.
Smad2 and Smad3 phosphorylation and subsequent translocation to the nucleus are required for TGF-␤1 signaling. Because EPA and DHA demonstrated an inhibitory effect on TGF-␤1-induced fibrosis ( Figure 5B through 5E), we tested the effects of EPA and DHA on the TGF-␤1-induced phosphorylation of Smad2 and Smad3. In cultured cardiac fibroblasts, TGF-␤1 treatment for 30 minutes induced robust phosphorylation of Smad2 (2.7-fold; PϽ0.01) and Smad3 (2.2-fold; PϽ0.01). Longer exposure (24 hours) to TGF-␤1 induced phosphorylation of Smad2 but not Smad3 ( Figure 6C through 6E). However, EPA and DHA (10 mol/L) failed to block TGF-␤1-induced phosphorylation of Smad2 and Smad3 ( Figure 6C through 6E) at either 30 minutes or 24 hours, which was consistent with our finding that fish oil did not inhibit TAC-induced phosphorylation of Smad2 in vivo ( Figure 4B and 4C) . Thus, the inhibitory effect of EPA and DHA on TGF-␤1-induced cardiac fibrosis is not due to inhibition of Smad phosphorylation.
EPA and DHA Block Nuclear Translocation of Phospho-Smad2 and -Smad3 Through the cGMP/PKG Pathway
Because TGF-␤1-induced phosphorylation of Smads was not blocked by DHA and EPA, we analyzed the ability of EPA and DHA to block TGF-␤1-induced nuclear translocation of phospho-Smad2 and -Smad3. In cultured cardiac fibroblasts, TGF-␤1 increased the nuclear localization of phospho-Smad2 (66%; PϽ0.01) and phospho-Smad3 (83%; PϽ0.01; Figure  7 ). TGF-␤1-induced nuclear translocation of both Smads was significantly blocked by EPA and DHA (phospho-Smad2, reduced to 15% with DHA and to 13% with EPA; phospho-Smad3, reduced to 14% with DHA and to 13% with EPA; Figure 7 ). Furthermore, 8-bromo-cGMP (1 mmol/L) blocked TGF-␤1-induced translocation of both phospho-Smad2 and -Smad3, whereas DT-3 reversed the effects of EPA and DHA on nuclear translocation of Smads in cardiac fibroblasts treated with TGF-␤1 ( Figure 7) . Therefore, EPA and DHA inhibition of TGF-␤1-induced fibrosis is mediated by blockage of phospho-Smad nuclear translocation.
EPA and DHA Increased Nitrite/Nitrate Production and Phosphorylated Endothelial Nitric Oxide Synthase and Endothelial Nitric Oxide Expression in Cardiac Fibroblasts
Nitric oxide (NO) increases cGMP production through activation of soluble guanylyl cyclase, 21, 22 and -3 PUFAs increase NO synthesis in humans. 23 Therefore, we tested the hypothesis that EPA and DHA increase NO production in cardiac fibroblasts. Because NO is rapidly metabolized, we measured the total intracellular level of nitrite (NO 2 Ϫ ) and nitrate (NO 3 Ϫ ), stable NO metabolites, as an index of total NO production. Twenty-four hours of treatment with EPA and DHA (10 mol/L) significantly increased nitrite and nitrate levels in cardiac fibroblasts (70% in EPA and 65% in DHA). We also examined whether NO production was induced with an increase in intracellular levels of cGMP. As expected, the cGMP analog 8-bromo-cGMP (0.1 and 1 mmol/L) did not induce NO production in cardiac fibroblasts ( Figure 8A ). This demonstrates that the increase of NO is not a result of increased intracellular cGMP.
To determine whether EPA and DHA enhance expression of phosphorylated endothelial nitric oxide synthase (eNOS) and eNOS, we measured phospho-eNOS and eNOS protein levels in cardiac fibroblasts. Treatment with 10 mol/L DHA or EPA significantly increased phospho-eNOS and eNOS protein levels in cardiac fibroblasts ( Figure 8B through 8D) . These results demonstrate that EPA and DHA increase phospho-eNOS and eNOS expression, thereby promoting NO production in cardiac fibroblasts.
To examine other possible mechanisms involved in cGMP production and degradation, 21, 22 we tested the effects of EPA and DHA on particulate guanylyl cyclase activity, cGMPspecific phosphodiesterases activity, and messenger RNA (mRNA) levels of ANP and BNP in cardiac fibroblasts. We found that EPA (10 mol/L) and DHA (10 mol/L) did not increase particulate guanylyl cyclase activity and did not inhibit cGMP-specific phosphodiesterases activity (data not shown). We also found that EPA (10 mol/L) and DHA (10 mol/L) significantly decreased ANP mRNA and did not change the BNP mRNA in cardiac fibroblasts (data not shown).
Discussion
In the present study, we investigated the effects of -3 PUFAs on the cardiac fibrotic response. Fischer et al 24 reported that a diet supplemented with -3 PUFAs inhibits left ventricle perivascular fibrosis in rats carrying human rennin and angiotensinogen transgenes, and Medeiros et al 25 reported that -3 PUFAs and palm oil (which is devoid of -3 PUFAs) reduce cardiac fibrosis in diabetic spontaneously hypertensive rats. However, in the above hypertension models, -3 PUFAs significantly decreased the systemic arterial blood pressure. Therefore, from the above studies, we cannot conclude that the antifibrotic effect of -3 PUFAs is independent of blood pressure. At the same time, both studies compared the group fed an -3 PUFA-supplemented diet and a control group fed a diet containing less total fatty acids, which makes the results more difficult to interpret. In the present study, which used an isocaloric control diet containing equal levels of total fatty acids, -3 PUFAs decreased pressure overload-induced cardiac fibrosis by 63% and consequently preserved cardiac function without changing the blood pressure or pressure gradients ( Table III in the onlineonly Data Supplement). Therefore, our results demonstrate an antifibrotic effect of -3 PUFAs that is independent of afterload.
We also identified a potential in vivo mechanism for this antifibrotic effect. Here, we found that in the heart, aortic constriction significantly increased the levels of active TGF-␤1 protein, phosphorylation of Smad2, transformation of cardiac fibroblasts, nonmyocyte proliferation, and the levels of collagen I and III mRNA. We also found that -3 PUFAs prevented the increase in transformation of cardiac fibroblasts, nonmyocyte proliferation, and collagen I and III mRNA without altering the levels of active TGF-␤1 protein and phosphorylation of Smad2. Therefore, our findings indicate that -3 PUFAs inhibit pressure overload-induced cardiac fibrosis by preventing cardiac fibroblast transformation, proliferation, and consequently collagen I and III gene expression. Our findings also indicate that -3 PUFAs do not inhibit TGF-␤1 fibrotic signaling at the level of the TGF-␤1 ligand, TGF-␤1 receptors, or phosphorylation of Smad2.
Using cultured adult mouse cardiac fibroblasts, we further identified the antifibrotic signaling of -3 PUFAs and its interaction with the fibrotic signaling of TGF-␤1. In our in vitro study, we saw increased -3 content and cGMP levels in DHA-and EPA-treated cardiac fibroblasts. These findings indicate that EPA and DHA can be incorporated into cardiac fibroblasts and activate cGMP signaling in cardiac fibroblasts. We also observed that EPA and DHA prevented TGF-␤1-induced proliferation, transformation, and collagen synthesis in cardiac fibroblasts and TGF-␤1-induced Smadresponsive promoter activity ( Figure I in the online-only Data Supplement). We also found that DT3, a highly selective PKG inhibitor, blocked the inhibitory effects of EPA and DHA on TGF-␤1-induced cardiac fibroblast proliferation, transformation, and collagen synthesis in cardiac fibroblasts. These findings suggest that EPA and DHA act through the cGMP/PKG pathway to achieve their antifibrotic effect in cardiac fibroblasts.
cGMP has an inhibitory effect on the TGF-␤1-induced fibrotic response. 9,10,26 Li 10 reported that disruption of nuclear translocation of Smad3 accounts for the antifibrotic effect of cGMP/PKG signaling against the TGF-␤1 signaling pathway. In our observations, EPA and DHA increased cGMP levels in cardiac fibroblasts in a dose-dependent manner. EPA, DHA, and 8-bromo-cGMP prevented TGF-␤1-induced nuclear translocation of phospho-Smad2 and phospho-Smad3 without affecting Smad2 and Smad3 phosphorylation in cardiac fibroblasts. In addition, DT3 reversed the inhibitory effects of 8-Br-cGMP, EPA, and DHA on the TGF-␤1-induced nuclear translocation of phospho-Smad2 and phospho-Smad3. These In the cell, NO-sensitive soluble guanylyl cyclase and natriuretic peptide-sensitive particulate guanylyl cyclase produce cGMP, whereas cGMP-specific phosphodiesterases hydrolyze cGMP. 21, 22 DHA increases NO synthesis and phospho-eNOS and eNOS expression levels. 27 NO promotes cGMP production through activation of NO-sensitive soluble guanylyl cyclase. 21, 22 In this study, we found that EPA and DHA significantly increased the expression levels of phospho-eNOS and eNOS and increased nitrite/nitrate levels in cardiac fibroblasts. We also found that EPA and DHA did not increase particulate guanylyl cyclase activity or ANP/ BNP production. Additionally, EPA and DHA did not inhibit cGMP-specific phosphodiesterase activity. Therefore, we postulate that EPA and DHA increase intracellular levels of cGMP by increasing phospho-eNOS and eNOS protein levels and NO production in cardiac fibroblasts.
TGF-␤1-induced phosphorylation of ERK1/2 is also involved in the TGF-␤1-induced fibrotic response in fibroblasts. 28 To determine whether EPA and DHA affect TGF-␤1-induced phosphorylation of ERK1/2, we tested phospho-ERK levels in cardiac fibroblasts after 1 hour of treatment of TGF-␤1 with or without pretreatment of EPA and DHA. TGF-␤1 (1 ng/mL) induced significant phosphorylation of ERK1/2 in cardiac fibroblasts, whereas EPA and DHA did not block this effect ( Figure III in the online-only Data Supplement).
In summary, we discovered an antifibrotic effect of EPA and DHA and established that EPA and DHA exert their antifibrotic effect through activation of the cGMP/PKG pathway. We extended the current understanding of the mechanism of the antifibrotic effects of cGMP by demonstrating that activation of PKG blocks TGF-␤1-induced nuclear translocation of phospho-Smad2 in cardiac fibroblasts. Our results also suggest that -3 PUFAs increase cGMP levels in cardiac fibroblasts by increasing phospho-eNOS and eNOS protein levels and NO production.
About 50% of heart failure cases are due to diastolic dysfunction. 2 One of the main causes of diastolic heart failure is cardiac fibrosis, and at present, no therapies are available to prevent or treat cardiac fibrosis. 4, 8, 29 Given the clinically proven safety and tolerance of oily fish, fish oil, and the DHAϩEPA preparations, a new clinical study of the therapeutic effect of -3 PUFAs on cardiac fibrosis and diastolic heart failure is warranted.
Study Limitations
This study examined the preventive effects of -3 PUFAs on a pressure-overloaded animal model that mimics only some aspects of the disease as it occurs in human. In this animal model, pressure overload induced an acute cardiac injury with a rapid progression that is more severe compared with human hypertension conditions. Another limitation of this study is that even though we fed -3 PUFAs at a reasonable level (1% energy), the red blood cell levels achieved were much higher compared with humans taking 2 g/d EPA and DHA. 30 Therefore, our findings should be explored with lower -3 PUFA doses. 
